$AVTX
Avalo Therapeutics, Inc. Stock $avtx

$avtx Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-K Financial Statement

#000162828020003395 Filed on March 11, 2020

Income Statement

Concept	2020 Q1	2019	2018 Q4
Revenue	$2.754M	$6.750M	-$6.310M
YoY Change	5.92%	-3.96%	-430.19%
Cost Of Revenue	$66.00K	-$566.5K	-$2.140M
YoY Change	-91.23%	-117.37%	-436.48%
Gross Profit	$2.688M	$7.317M	-$4.180M
YoY Change	45.5%	94.2%	-427.84%
Gross Profit Margin	97.6%	108.39%
Selling, General & Admin	$3.353M	$11.61M	-$2.670M
YoY Change	9.15%	4.98%	-166.85%
% of Gross Profit	124.74%	158.64%
Research & Development	$4.768M	$11.76M	$2.010M
YoY Change	40.19%	103.3%	2.5%
% of Gross Profit	177.38%	160.78%
Depreciation & Amortization	$453.0K	$3.884M	$1.220M
YoY Change	-58.76%	-14.74%	197.56%
% of Gross Profit	16.85%	53.08%
Operating Expenses	$8.121M	$23.37M	-$2.530M
YoY Change	-34.69%	-59.45%	-142.49%
Operating Profit	-$31.41M	-$16.14M	-$1.650M
YoY Change	527.64%	-54.39%	-64.74%
Interest Expense	$10.00K	$121.3K	$730.0K
YoY Change	-66.91%	646.12%	2254.84%
% of Operating Profit
Other Income/Expense, Net	$7.101M	$147.0K	$0.00
YoY Change	-26635.87%	167.57%
Pretax Income	-$24.31M	-$15.99M	-$920.0K
YoY Change	383.18%	-54.73%	-78.9%
Income Tax	-$2.200M	$280.3K	-$140.0K
% Of Pretax Income
Net Earnings	-$21.12M	-$16.07M	-$7.220M
YoY Change	183.3%	-59.87%	133.58%
Net Earnings / Revenue	-766.78%	-238.1%
Basic Earnings Per Share
Diluted Earnings Per Share	-$4.70	-$4.498M	-$2.11
COMMON SHARES
Basic Shares Outstanding	57.61M shares		40.81M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q1	2019	2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$20.37M	$11.24M	$10.65M
YoY Change	26.36%	5.56%	331.17%
Cash & Equivalents	$5.659M	$3.609M	$10.65M
Short-Term Investments	$14.71M	$7.629M	$0.00
Other Short-Term Assets	$840.0K	$1.222M	$4.880M
YoY Change	-36.84%	-74.97%	597.14%
Inventory	$16.28K	$21.33K	$317.9K
Prepaid Expenses
Receivables	$2.190M	$1.002M	$820.0K
Other Receivables	$2.064M	$4.241M	$5.262M
Total Short-Term Assets	$25.49M	$17.72M	$21.93M
YoY Change	-4.71%	-19.19%	105.47%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.417M	$1.448M	$586.5K
YoY Change	-4.08%	146.83%	1214.7%
Goodwill	$14.41M		$14.40M
YoY Change	-12.2%		17.17%
Intangibles	$2.696M		$3.765M
YoY Change	-91.06%		-78.68%
Long-Term Investments
YoY Change
Other Assets	$110.0K	$102.0K	$29.56M
YoY Change	37.5%	-99.66%	22638.46%
Total Long-Term Assets	$18.63M	$18.38M	$48.32M
YoY Change	-61.28%	-61.95%	50.37%
TOTAL ASSETS
Total Short-Term Assets	$25.49M	$17.72M	$21.93M
Total Long-Term Assets	$18.63M	$18.38M	$48.32M
Total Assets	$44.12M	$36.11M	$70.25M
YoY Change	-41.07%	-48.6%	64.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.726M	$2.078M	$1.446M
YoY Change	118.17%	43.66%	11.33%
Accrued Expenses	$6.190M	$5.565M	$5.370M
YoY Change	-43.78%	3.55%	-28.69%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$1.050M
YoY Change
Total Short-Term Liabilities	$15.33M	$12.16M	$26.22M
YoY Change	-45.51%	-53.62%	136.41%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$14.33M
YoY Change	-100.0%
Other Long-Term Liabilities	$1.094M	$2.867M	$385.5K
YoY Change	-7.99%	-87.57%	1488.32%
Total Long-Term Liabilities	$1.094M	$2.867M	$14.71M
YoY Change	-92.94%	-87.57%	60518.82%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.33M	$12.16M	$26.22M
Total Long-Term Liabilities	$1.094M	$2.867M	$14.71M
Total Liabilities	$18.53M	$15.11M	$49.34M
YoY Change	-64.19%	-69.37%	230.11%
SHAREHOLDERS EQUITY
Retained Earnings	-$135.4M		-$98.22M
YoY Change	28.11%		68.86%
Common Stock	$59.56K		$40.80K
YoY Change	39.31%		30.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$25.59M	$21.00M	$20.91M
YoY Change
Total Liabilities & Shareholders Equity	$44.12M	$36.11M	$70.25M
YoY Change	-41.07%	-48.6%	64.11%

Cashflow Statement

Concept	2020 Q1	2019	2018 Q4
OPERATING ACTIVITIES
Net Income	-$21.12M	-$16.07M	-$7.220M
YoY Change	183.3%	-59.87%	133.58%
Depreciation, Depletion And Amortization	$453.0K	$3.884M	$1.220M
YoY Change	-58.76%	-14.74%	197.56%
Cash From Operating Activities	-$5.739M	-$19.13M	-$1.980M
YoY Change	83.85%	511.69%	-22.35%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$262.0K	$490.0K
YoY Change	-100.0%	-53.58%	4800.0%
Acquisitions		$0.00
YoY Change		-100.0%
Other Investing Activities		-$181.0K	$0.00
YoY Change		-112.66%	-100.0%
Cash From Investing Activities	-$1.251M	-$443.0K	-$490.0K
YoY Change	653.76%	-151.19%	-97.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$8.976M
YoY Change	-100.0%
Debt Paid & Issued, Net	$0.00	$256.1K
YoY Change	-100.0%
Cash From Financing Activities	$9.098M	$12.56M	6.160M
YoY Change	3.19%	20.72%	61500.0%
NET CHANGE
Cash From Operating Activities	-$5.739M	-$19.13M	-1.980M
Cash From Investing Activities	-$1.251M	-$443.0K	-490.0K
Cash From Financing Activities	$9.098M	$12.56M	6.160M
Net Change In Cash	$2.108M	-$7.018M	3.690M
YoY Change	-61.88%	-186.2%	-117.21%
FREE CASH FLOW
Cash From Operating Activities	-$5.739M	-$19.13M	-$1.980M
Capital Expenditures	$0.00	$262.0K	$490.0K
Free Cash Flow	-$5.739M	-$19.40M	-$2.470M
YoY Change	74.57%	425.29%	-3.52%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019	cerc	Accounts Receivable Payment Terms AccountsReceivablePaymentTerms	P30D
CY2019Q4	cerc	Accounts Receivable Prompt Payment Discount AccountsReceivablePromptPaymentDiscount	0.02
CY2018Q4	cerc	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	1112378	USD
CY2019Q4	cerc	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	360016	USD
CY2018Q4	cerc	Accrued Medicaid Rebates AccruedMedicaidRebates	50246	USD
CY2019Q4	cerc	Accrued Medicaid Rebates AccruedMedicaidRebates	118271	USD
CY2018Q4	cerc	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	278132	USD
CY2019Q4	cerc	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	920901	USD
CY2018Q4	cerc	Accrued Sales Returns And Allowances AccruedSalesReturnsAndAllowances	1465419	USD
CY2019Q4	cerc	Accrued Sales Returns And Allowances AccruedSalesReturnsAndAllowances	2284175	USD
CY2018	cerc	Amortization Of Inventory Fair Value Adjustment AmortizationOfInventoryFairValueAdjustment	300573	USD
CY2019	cerc	Amortization Of Inventory Fair Value Adjustment AmortizationOfInventoryFairValueAdjustment	107271	USD
CY2018	cerc	Amortizationof Intangible Assets Continuing Operations AmortizationofIntangibleAssetsContinuingOperations	1828552	USD
CY2019	cerc	Amortizationof Intangible Assets Continuing Operations AmortizationofIntangibleAssetsContinuingOperations	1338996	USD
CY2019Q4	cerc	Capital Stock Shares Authorized CapitalStockSharesAuthorized	205000000	shares
CY2018	cerc	Cash Acquired From Asset Acquistion CashAcquiredFromAssetAcquistion	1429877	USD
CY2019	cerc	Cash Acquired From Asset Acquistion CashAcquiredFromAssetAcquistion	0	USD
CY2018	cerc	Class Of Warrant Or Right Distribution Adjustment ClassOfWarrantOrRightDistributionAdjustment	1657383	USD
CY2019	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2019Q4	cerc	Deferred Tax Assets Installment Sale DeferredTaxAssetsInstallmentSale	441305	USD
CY2018	cerc	Class Of Warrant Or Right Distribution Adjustment Continuing Operations ClassOfWarrantOrRightDistributionAdjustmentContinuingOperations	1657383	USD
CY2018	cerc	Class Of Warrant Or Right Distribution Adjustment Discontinued Operations ClassOfWarrantOrRightDistributionAdjustmentDiscontinuedOperations	0	USD
CY2019Q4	cerc	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	296259	USD
CY2018Q4	cerc	Deferred Tax Assets Installment Sale DeferredTaxAssetsInstallmentSale	508291	USD
CY2018Q4	cerc	Deferred Tax Assets Tax Difference In Tangible And Intangible Assets DeferredTaxAssetsTaxDifferenceInTangibleAndIntangibleAssets	2968764	USD
CY2019Q4	cerc	Deferred Tax Assets Tax Difference In Tangible And Intangible Assets DeferredTaxAssetsTaxDifferenceInTangibleAndIntangibleAssets	1968008	USD
CY2019Q4	cerc	Disposal Group Including Discontinued Operation Guarantee DisposalGroupIncludingDiscontinuedOperationGuarantee	1800000	USD
CY2018	cerc	Effective Income Tax Rate Reconciliation Built In Loss Percent EffectiveIncomeTaxRateReconciliationBuiltInLossPercent	0.0498
CY2019	cerc	Effective Income Tax Rate Reconciliation Built In Loss Percent EffectiveIncomeTaxRateReconciliationBuiltInLossPercent	-0.0013
CY2018	cerc	Effective Income Tax Rate Reconciliation Change In Fair Value Of Contingent Consideration EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentConsideration	0.0000
CY2019	cerc	Effective Income Tax Rate Reconciliation Change In Fair Value Of Contingent Consideration EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentConsideration	0.0165
CY2018	cerc	Effective Income Tax Rate Reconciliation Net Operating Loss Adjustment Per Section382 Percent EffectiveIncomeTaxRateReconciliationNetOperatingLossAdjustmentPerSection382Percent	-0.0074
CY2019	cerc	Effective Income Tax Rate Reconciliation Net Operating Loss Adjustment Per Section382 Percent EffectiveIncomeTaxRateReconciliationNetOperatingLossAdjustmentPerSection382Percent	-0.0186
CY2018	cerc	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.0010
CY2019	cerc	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.0047
CY2018	cerc	Fair Value Adjustment Of Warrants And Investor Rights Obligation FairValueAdjustmentOfWarrantsAndInvestorRightsObligation	-25010	USD
CY2019	cerc	Fair Value Adjustment Of Warrants And Investor Rights Obligation FairValueAdjustmentOfWarrantsAndInvestorRightsObligation	3888	USD
CY2018	cerc	Fair Value Measurements Changes In Valuation Techniques Number FairValueMeasurementsChangesInValuationTechniquesNumber	0	class_of_stock
CY2019	cerc	Fair Value Measurements Changes In Valuation Techniques Number FairValueMeasurementsChangesInValuationTechniquesNumber	0	class_of_stock
CY2018Q4	cerc	Finite Lived Intangible Assets Accumulated Impairment FiniteLivedIntangibleAssetsAccumulatedImpairment	1861562	USD
CY2018	cerc	Impairmentof Intangible Assets Excluding Goodwill Continuing Operations ImpairmentofIntangibleAssetsExcludingGoodwillContinuingOperations	1861562	USD
CY2019	cerc	Impairmentof Intangible Assets Excluding Goodwill Continuing Operations ImpairmentofIntangibleAssetsExcludingGoodwillContinuingOperations	0	USD
CY2019	cerc	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	125506	USD
CY2018	cerc	Increase Decrease In License Obligation Noncurrent IncreaseDecreaseInLicenseObligationNoncurrent	0	USD
CY2019	cerc	Increase Decrease In License Obligation Noncurrent IncreaseDecreaseInLicenseObligationNoncurrent	-1250000	USD
CY2019Q4	cerc	Lessee Operating Lease Liability Annual Base Rent LesseeOperatingLeaseLiabilityAnnualBaseRent	161671	USD
CY2019	cerc	Lessee Operating Lease Number Of Contracts LesseeOperatingLeaseNumberOfContracts	1	contract
CY2019	cerc	Lessee Operating Lease Number Of Renewal Options LesseeOperatingLeaseNumberOfRenewalOptions	2	renewal_option
CY2019	cerc	Lessee Operating Lease Remaining Lease Team LesseeOperatingLeaseRemainingLeaseTeam	P10Y1M
CY2019	cerc	Lessee Operating Lease Rent Abatement Period LesseeOperatingLeaseRentAbatementPeriod	P12M
CY2018Q4	cerc	License Obligation Noncurrent LicenseObligationNoncurrent	1250000	USD
CY2019Q4	cerc	License Obligation Noncurrent LicenseObligationNoncurrent	0	USD
CY2019Q4	cerc	Loans And Lease Receivable Number Of Promissory Notes LoansAndLeaseReceivableNumberOfPromissoryNotes	2	note
CY2019Q4	cerc	Loans Receivable Fixed Interest Rate LoansReceivableFixedInterestRate	0.05
CY2018Q4	cerc	Minimum Sales Commitments Royalties Payable And Purchase Obligations Current MinimumSalesCommitmentsRoyaltiesPayableAndPurchaseObligationsCurrent	8954521	USD
CY2019Q4	cerc	Minimum Sales Commitments Royalties Payable And Purchase Obligations Current MinimumSalesCommitmentsRoyaltiesPayableAndPurchaseObligationsCurrent	75000	USD
CY2015Q4	cerc	Number Of Class Of Stock Authorized NumberOfClassOfStockAuthorized	2	class_of_stock
CY2019Q4	cerc	Operating Lease Right Of Use Asset Before Accumulated Amortization OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization	718628	USD
CY2019	cerc	Operating Leases Rent Expense Annual Increase Percent OperatingLeasesRentExpenseAnnualIncreasePercent	0.025
CY2017Q3	cerc	Potential Future Regulatory Milestone PotentialFutureRegulatoryMilestone	20000000	USD
CY2018	cerc	Proceeds From Option Or Warrant Exercises ProceedsFromOptionOrWarrantExercises	1083953	USD
CY2019	cerc	Proceeds From Option Or Warrant Exercises ProceedsFromOptionOrWarrantExercises	836188	USD
CY2019Q4	cerc	Property Plant And Equipment And Operating Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	78169	USD
CY2019Q4	cerc	Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	1447663	USD
CY2019Q4	cerc	Property Plant And Equipment And Operating Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	1525832	USD
CY2019Q3	cerc	Royalty Agreement Buyout Option Percentage Of Net Present Value Of Royalty Payments RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments	0.75
CY2019Q3	cerc	Royalty Agreement Payment Received RoyaltyAgreementPaymentReceived	2000000	USD
CY2019Q3	cerc	Royalty Agreement Period After Public Launch To Terminate Agreement RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement	P3Y
CY2018	cerc	Share Based Compensation Arrangement By Share Based Payment Award Share Reserve Increase As Percent ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent	0.04
CY2018	cerc	Stock Issued During Period Value Acquisitions Contingent Shares StockIssuedDuringPeriodValueAcquisitionsContingentShares	0	USD
CY2018	cerc	Stock Issued During Period Value New Issues Private Placement StockIssuedDuringPeriodValueNewIssuesPrivatePlacement	3857106	USD
CY2019	cerc	Stock Issued During Period Value New Issues Private Placement StockIssuedDuringPeriodValueNewIssuesPrivatePlacement	3708602	USD
CY2018	cerc	Stock Issued During Period Value Stock Options And Warrants Exercised StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised	1083953	USD
CY2019	cerc	Stock Issued During Period Value Stock Options And Warrants Exercised StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised	836188	USD
CY2018	cerc	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	5685038	USD
CY2019	dei	Amendment Flag AmendmentFlag	false
CY2019	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2019	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019	dei	Document Period End Date DocumentPeriodEndDate	2019-12-31
CY2019	dei	Document Type DocumentType	10-K
CY2019	dei	Entity Central Index Key EntityCentralIndexKey	0001534120
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	57609033	shares
CY2019	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2019	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2019	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2019	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2019Q2	dei	Entity Public Float EntityPublicFloat	81295262	USD
CY2019	dei	Entity Registrant Name EntityRegistrantName	Cerecor Inc.
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2019	dei	Entity Small Business EntitySmallBusiness	true
CY2019	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1446141	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2077524	USD
CY2018Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	822327	USD
CY2019Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	1001645	USD
CY2018Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	2032258	USD
CY2019Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	551671	USD
CY2018Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	14328879	USD
CY2019Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	5640252	USD
CY2018Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	235721	USD
CY2019Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	120056	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	132163	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	119082157	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	135238941	USD
CY2019	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	33959	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2431063	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2462796	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2431063	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2462796	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1815872	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1338996	USD
CY2018Q4	us-gaap	Assets Assets	70250721	USD
CY2019Q4	us-gaap	Assets Assets	36108970	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	21931893	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	17724016	USD
CY2018Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	4132445	USD
CY2019Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	497577	USD
CY2018	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	58366	USD
CY2019	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1009169	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	0	USD
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	859670	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	0	USD
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	396540	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	0	USD
CY2018	us-gaap	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Intangibles BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles	6000	USD
CY2018Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Long Term Debt BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt	15075000	USD
CY2019Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Long Term Debt BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt	0	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10646301	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3609438	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3600000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2605499	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10746756	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3728918	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8141257	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7017838	USD
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40804189	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44384222	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40804189	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44384222	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	40804	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	44384	USD
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3260668	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	-566523	USD
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	42406871	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	22887759	USD
CY2018	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	20560	USD
CY2019	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	54572	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-53281	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	209001	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-32721	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	263573	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-52235	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10725136	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14342005	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	24458	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-16745	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	16743	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	69238	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	85981	USD
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	35490	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-7715	USD
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	10655898	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	14256024	USD
CY2018Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	577490	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4421423	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7596955	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	252095	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1070738	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	465430	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	321748	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1922736	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1872442	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	277633	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	399885	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	69238	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	85981	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	167943	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	160474	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	120863	USD
CY2018	us-gaap	Depreciation Depreciation	22515	USD
CY2019	us-gaap	Depreciation Depreciation	119488	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4554963	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3883567	USD
CY2018	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	0	USD
CY2019	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	7964924	USD
CY2018	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare	-0.14
CY2018Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	29476249	USD
CY2019Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	0	USD
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.20
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0014
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0175
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.1453
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.2707
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0070
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0513
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.1117
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0000
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1953065	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1591964	USD
CY2018Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	0	USD
CY2019Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	7628947	USD
CY2018	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	0	USD
CY2019	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	53932	USD
CY2018	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	0	USD
CY2019	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	53932	USD
CY2018Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2019Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2018Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2019Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2018	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	110923	USD
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	1256211	USD
CY2018	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P2Y10M17D
CY2019	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P1Y10M21D
CY2018Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2132184	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2779742	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	0	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1320246	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	0	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	0	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	0	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1106012	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	7759000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5206000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3765254	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2426258	USD
CY2018	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	150000	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10511207	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10123320	USD
CY2017Q4	us-gaap	Goodwill Goodwill	12290247	USD
CY2018Q4	us-gaap	Goodwill Goodwill	14409088	USD
CY2018Q4	us-gaap	Goodwill Goodwill	14400000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	14409088	USD
CY2019Q4	us-gaap	Goodwill Goodwill	14400000	USD
CY2018	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	3778001	USD
CY2018Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0	USD
CY2018	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	1861562	USD
CY2018	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	1900000	USD
CY2019	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	1449121	USD
CY2019Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0	USD
CY2018	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	-1659160	USD
CY2019Q4	us-gaap	Guarantee Obligations Maximum Exposure GuaranteeObligationsMaximumExposure	25200000	USD
CY2019Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	0	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	222530	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1658333	USD
CY2018	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-226890	USD
CY2019	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-1480587	USD
CY2018	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-3752390	USD
CY2019	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2018	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-35323565	USD
CY2019	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-15990437	USD
CY2018	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-35274099	USD
CY2019	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-16270753	USD
CY2018	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-35274099	USD
CY2018	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-1.06
CY2018	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-4778711	USD
CY2018	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-4778711	USD
CY2019	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	198206	USD
CY2019Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-49466	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	280316	USD
CY2018	us-gaap	Income Taxes Paid IncomeTaxesPaid	354000	USD
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	1803665	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	82451	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1019358	USD
CY2019	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	0	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	311199	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-532947	USD
CY2018	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	7792259	USD
CY2019	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-6835395	USD
CY2018	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	385517	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	USD
CY2018	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	2277255	USD
CY2019	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-5120247	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	241641	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	917016	USD
CY2017Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	7286688	USD
CY2018Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	3765254	USD
CY2019Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	2426258	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3765254	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2426258	USD
CY2018	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	16261	USD
CY2019	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	121326	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	525000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	1050000	USD
CY2018Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	497949	USD
CY2019Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	46705	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	317923	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	21334	USD
CY2018Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	191418	USD
CY2019Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	25371	USD
CY2018	us-gaap	Inventory Write Down InventoryWriteDown	174944	USD
CY2018Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	11392	USD
CY2019	us-gaap	Inventory Write Down InventoryWriteDown	36577	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	26216579	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12160459	USD
CY2018Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	7549631	USD
CY2019Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	3891012	USD
CY2019Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.077
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1860455	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1000746	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	155815	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	182544	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	178092	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	173748	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	169510	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	592675	USD
CY2019Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2019Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P10Y
CY2018Q4	us-gaap	Liabilities Liabilities	49342973	USD
CY2019Q4	us-gaap	Liabilities Liabilities	15113405	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	70250721	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	36108970	USD
CY2018Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	21025099	USD
CY2019Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	1755000	USD
CY2019Q4	us-gaap	Loans And Leases Receivable Net Reported Amount LoansAndLeasesReceivableNetReportedAmount	4100000	USD
CY2019Q4	us-gaap	Loans Receivable With Fixed Rates Of Interest1 LoansReceivableWithFixedRatesOfInterest1	5000000	USD
CY2017Q4	us-gaap	Minority Interest Ownership Percentage By Noncontrolling Owners MinorityInterestOwnershipPercentageByNoncontrollingOwners	0.10
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10403898	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12559496	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	865461	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-443002	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3128102	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19134332	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19100000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-40052810	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-16100000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-16072547	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	41700000	USD
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	54928	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	146971	USD
CY2019	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2019	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reporting_unit
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-35378493	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-16137408	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	160767	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1267780	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	155815	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1111965	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	0	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	718626	USD
CY2018	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	239259	USD
CY2019Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	52200000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	279397	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	169869	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	385517	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1111965	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	13657	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-24399	USD
CY2018Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	5262213	USD
CY2019Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	4240572	USD
CY2018	us-gaap	Paid In Kind Interest PaidInKindInterest	302882	USD
CY2019	us-gaap	Paid In Kind Interest PaidInKindInterest	0	USD
CY2018	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	294435	USD
CY2019	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	881932	USD
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	33959	USD
CY2018	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1	USD
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2019	us-gaap	Payments To Acquire Loans Receivable PaymentsToAcquireLoansReceivable	4139401	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	564415	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	262013	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2857143	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2857143	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2857143	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2857143	shares
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	2857	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	2857	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	731954	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	706968	USD
CY2018	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	0	USD
CY2019	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	3958412	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8975960	USD
CY2018	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	3857106	USD
CY2019	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	3708602	USD
CY2018	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	72236	USD
CY2019	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	210777	USD
CY2018	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	5685038	USD
CY2019	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	718675	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	586512	USD
CY2018	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	256140	USD
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	18730	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	17535	USD
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	34773613	shares
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	81725	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	27859608	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	101945	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-98218070	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	20907748	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	20995565	USD
CY2018	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	5786635	USD
CY2019	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	11764133	USD
CY2018	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	18723952	USD
CY2017	us-gaap	Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit	2200000	USD
CY2018	us-gaap	Undistributed Continuing Operation Earnings Loss Allocation To Participating Securities Basic UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic	-36931482	USD
CY2018	us-gaap	Undistributed Discontinued Operation Earnings Loss Allocation To Participating Securities Basic UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic	-4778711	USD
CY2018	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	-41710193	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-114300000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-114290617	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7028378	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6750351	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	743025	USD
CY2018	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	545218	USD
CY2019	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1484044	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	2431063	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	2532257	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	19971554	USD
CY2018	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	72236	USD
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	210777	USD
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8975960	USD
CY2019	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2019	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;text-align:justify;text-indent:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company maintains a portion of its cash and cash equivalent balances in the form of a money market account with a financial institution that management believes to be creditworthy. The Company has no financial instruments with off‑balance sheet risk of loss.</font></div></div>
CY2019	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Business</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#ff0000;"></font><font style="font-family:inherit;font-size:10pt;">Cerecor Inc. (the "Company" or "Cerecor") is a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases. The Company is advancing an emerging clinical-stage pipeline of innovative therapies that address unmet patient needs within rare pediatric and orphan diseases. The Company's pediatric rare disease pipeline is led by CERC-801, CERC-802 and CERC-803 ("CERC-800 compounds"), which are therapies for inherited metabolic disorders known as Congenital Disorders of Glycosylation ("CDGs"). The U.S. Food and Drug Administration ("FDA") granted Rare Pediatric Disease designation ("RPDD") and Orphan Drug Designation ("ODD") to all </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> CERC-800 compounds, thus potentially qualifying the Company to receive a Priority Review Voucher ("PRV") upon approval of each New Drug Application ("NDA"). Each PRV may be sold or transferred an unlimited number of times. The Company plans to leverage the 505(b)(2) NDA pathway for all </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> compounds to accelerate development and approval. Additionally, CERC-801 and CERC-802 were granted Fast Track Designation ("FTD") from the FDA, which can help facilitate and potentially expedite development of each compound. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is also developing CERC-002, CERC-006 and CERC-007. CERC-007 is an anti-IL-18 monoclonal antibody being developed for the treatment of autoimmune inflammatory diseases such as Adult Onset Stills Disease ("AOSD") and Multiple Myeloma. CERC-006 is a dual mTOR inhibitor being developed for the treatment of complex Lymphatic Malformations. CERC-002 is an anti-LIGHT (</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">L</font><font style="font-family:inherit;font-size:10pt;">ymphotoxin-like, exhibits </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">I</font><font style="font-family:inherit;font-size:10pt;">nducible expression, and competes with HSV </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">G</font><font style="font-family:inherit;font-size:10pt;">lycoprotein D for </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">H</font><font style="font-family:inherit;font-size:10pt;">VEM, a receptor expressed by </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">T</font><font style="font-family:inherit;font-size:10pt;"> lymphocytes) monoclonal antibody being developed for the treatment of Pediatric-onset Crohn's Disease. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company continues to explore strategic alternatives for its non-core assets, including CERC-301, as well as its sole commercialized product, Millipred</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;">, an oral prednisolone indicated across a wide variety of inflammatory conditions.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 3, 2020, the Company consummated its two-step merger (the "Merger") with Aevi Genomic Medicine, Inc. ("Aevi") in accordance with the terms of the Agreement and Plan of Merger and Reorganization (the "Merger Agreement") dated December 5, 2019. The Merger consideration included stock valued at approximately </font><font style="font-family:inherit;font-size:10pt;">$15.6 million</font><font style="font-family:inherit;font-size:10pt;">, resulting in the issuance of approximately </font><font style="font-family:inherit;font-size:10pt;">3.9 million</font><font style="font-family:inherit;font-size:10pt;"> shares of Cerecor common stock to Aevi stockholders, forgiveness of a </font><font style="font-family:inherit;font-size:10pt;">$4.1 million</font><font style="font-family:inherit;font-size:10pt;"> loan that Cerecor loaned Aevi in December 2019 (the "Aevi Loan"), and contingent value rights ("CVRs") for up to an additional </font><font style="font-family:inherit;font-size:10pt;">$6.5 million</font><font style="font-family:inherit;font-size:10pt;"> in subsequent payments based on clinical and/or regulatory milestones. As part of the Merger, Cerecor acquired CERC-002, CERC-006 and CERC-007, expanding Cerecor's pipeline to </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> clinical stage assets being developed for rare pediatric and orphan diseases. Effective upon the consummation of the Merger, Cerecor entered into an employment agreement with Mike Cola for him to serve as Cerecor's Chief Executive Officer, an employment agreement with Dr. Garry Neil for him to serve as Cerecor's Chief Medical Officer and appointed Mike Cola and Sol J. Barer, Ph.D. to the Company's Board of Directors. See Note 17 for more information. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the fourth quarter of 2019, the Company entered into, and closed on, an asset purchase agreement (the "Aytu Purchase Agreement") with Aytu BioScience, Inc. (“Aytu”) to sell the Company’s rights, title and interest in, assets relating to its pediatric portfolio, namely Aciphex</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">® </sup></font><font style="font-family:inherit;font-size:10pt;">Sprinkle™, Cefaclor for Oral Suspension, Karbinal™ ER, Flexichamber™, Poly-Vi-Flor</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> and Tri-Vi-Flor™ (the "Pediatric Portfolio"), as well as the corresponding commercial infrastructure consisting of the right to offer employment to Cerecor’s sales force and the assignment of supporting commercial contracts (the "Aytu Divestiture"). Aytu paid consideration of </font><font style="font-family:inherit;font-size:10pt;">$4.5 million</font><font style="font-family:inherit;font-size:10pt;"> in cash and approximately </font><font style="font-family:inherit;font-size:10pt;">9.8 million</font><font style="font-family:inherit;font-size:10pt;"> shares of Aytu convertible preferred stock (the "Investment"), and assumed certain of the Company’s liabilities, including the Company’s payment obligations payable to Deerfield CSF, LLC of $</font><font style="font-family:inherit;font-size:10pt;">15.1 million</font><font style="font-family:inherit;font-size:10pt;"> and other liabilities of </font><font style="font-family:inherit;font-size:10pt;">$11.0 million</font><font style="font-family:inherit;font-size:10pt;">. The Company recognized a gain of </font><font style="font-family:inherit;font-size:10pt;">$8.0 million</font><font style="font-family:inherit;font-size:10pt;"> upon the closing of the Aytu Divestiture. As a result of the sale of the Pediatric Portfolio, the Pediatric Portfolio met all conditions required in order to be classified as discontinued operations. Therefore, operating results from the Pediatric Portfolio are reported within income (loss) from discontinued operations, net of tax (inclusive of gain on sale) for all periods presented and the gain recognized as a result of the sale is reported within income from discontinued operations, net of tax (inclusive of gain on sale) for the year ended December 31, 2019. In addition, assets and liabilities related to the Pediatric Portfolio are reported as assets and liabilities of discontinued operations in the accompanying consolidated balance sheets as of December 31, 2019 and 2018. See Note 3 for more information regarding the Aytu Divestiture and its accounting treatment.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cerecor was incorporated in 2011, commenced operations in the second quarter of 2011 and completed an initial public offering in October 2015.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">During the first quarter of 2019, the Company closed on an underwritten public offering of common stock for </font><font style="font-family:inherit;font-size:10pt;">1,818,182</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock of the Company, at a price to the public of </font><font style="font-family:inherit;font-size:10pt;">$5.50</font><font style="font-family:inherit;font-size:10pt;"> per share ("public price"). Armistice Capital Master Fund Ltd. ("Armistice"), the Company's largest stockholder, participated in the offering by purchasing </font><font style="font-family:inherit;font-size:10pt;">363,637</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock of the Company at the public price. Cerecor director, Steven J. Boyd, is Armistice's Chief Investment Officer. The net proceeds of the offering were approximately </font><font style="font-family:inherit;font-size:10pt;">$9.0 million</font><font style="font-family:inherit;font-size:10pt;">. During the third quarter of 2019, the Company entered into a securities purchase agreement with Armistice, pursuant to which, the Company sold </font><font style="font-family:inherit;font-size:10pt;">1,200,000</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock for a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$3.132</font><font style="font-family:inherit;font-size:10pt;"> per share. Net proceeds of the private placement were approximately </font><font style="font-family:inherit;font-size:10pt;">$3.7 million</font><font style="font-family:inherit;font-size:10pt;">. During the fourth quarter of 2019, the Company entered into, and subsequently closed on, the Aytu Purchase Agreement to sell the Company's rights, title and interest in, assets relating to its Pediatric Portfolio and related commercial infrastructure for a combination of cash and preferred stock (</font><font style="font-family:inherit;font-size:10pt;">$4.5 million</font><font style="font-family:inherit;font-size:10pt;"> in cash, and approximately </font><font style="font-family:inherit;font-size:10pt;">9.8 million</font><font style="font-family:inherit;font-size:10pt;"> shares of Aytu convertible preferred stock) and the assumption of certain of the Company's liabilities including the Company’s payment obligations payable to Deerfield of </font><font style="font-family:inherit;font-size:10pt;">$15.1 million</font><font style="font-family:inherit;font-size:10pt;"> and certain other liabilities of approximately </font><font style="font-family:inherit;font-size:10pt;">$11.0 million</font><font style="font-family:inherit;font-size:10pt;">. During the first quarter of 2020, the Company closed on a registered direct offering with institutional investors of </font><font style="font-family:inherit;font-size:10pt;">1,306,282</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock at a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$3.98</font><font style="font-family:inherit;font-size:10pt;"> per share. Armistice participated in the offering by purchasing </font><font style="font-family:inherit;font-size:10pt;">1,256,282</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock from the Company. The net proceeds of the offering were approximately </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to meet its cash flow needs, the Company applies a disciplined decision-making methodology as it evaluates the optimal allocation of the Company's resources between investing in the Company's existing pipeline assets and acquisitions or in-licensing of new assets. For the year ended December 31, 2019, Cerecor generated a net loss of </font><font style="font-family:inherit;font-size:10pt;">$16.1 million</font><font style="font-family:inherit;font-size:10pt;"> and negative cash flow from operations of </font><font style="font-family:inherit;font-size:10pt;">$19.1 million</font><font style="font-family:inherit;font-size:10pt;">. As of December 31, 2019, Cerecor had an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$114.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$3.6 million</font><font style="font-family:inherit;font-size:10pt;"> in cash and cash equivalents. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern; however, the Company expects to incur additional losses in the future in connection with research and development activities and will require additional financing to fund its operations and to continue to execute its strategy. The Company plans to use its current cash on hand and the anticipated cash flows from the Company's profits from Millipred product sales and/or the potential proceeds from the out-license or sale of Millipred to a third party to offset costs related to its orphan disease pipeline assets, business development, and costs associated with its organizational infrastructure; however, Cerecor expects to continue to incur significant expenses and operating losses for the immediate future as it continues to invest in the Company's pipeline assets. The Company’s ability to continue as a going concern through 2020 is dependent upon the Company’s ability to raise additional equity and/or debt capital; however, there can be no assurance that such capital will be available in sufficient amounts or on terms acceptable to the Company. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Over the long term, the Company's ultimate ability to achieve and maintain profitability is dependent on, among other things, the development, regulatory approval, and commercialization of its pipeline assets, and the potential sale of any PRVs it receives, all being adequate to support its cost structure and pipeline asset development.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These conditions raise substantial doubt about its ability to continue as a going concern within one year after the date that the financial statements are issued. To alleviate these conditions, the Company is evaluating the potential out-licensing or sale of Millipred to a third party and some combination of rights to future PRV sales, equity or debt financings, collaborations, out-licensing arrangements, strategic alliances, federal and private grants, marketing, distribution or licensing arrangements, the sale of current or future assets or possible monetization of the Company's holdings of Aytu equity. If the Company raises additional funds through collaborations, strategic alliances or licensing arrangements with third parties, the Company might have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible or suspend or curtail planned programs. Due to the uncertainty regarding future financings and/or other potential options to raise additional funds, management has concluded that substantial doubt exists with respect to the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued.</font></div></div>
CY2019	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">    </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures. On an ongoing basis, management evaluates its estimates, including estimates related to but not limited to, revenue recognition, cost of product sales, stock-based compensation, fair value measurements (including those relating to contingent consideration, equity Investment in Aytu, and guaranteed liabilities), cash flows used in management's going concern assessment, income taxes, goodwill and other intangible assets, and clinical trial accruals. The Company bases its estimates on historical experience and other market‑specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain estimates related specifically to the Pediatric Portfolio, such as revenue, cost of product sales, fair value measurement (including those relating to contingent consideration), goodwill, and other intangible assets have been reclassified under discontinued operations and included in assets and liabilities of discontinued operations. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>

Files In Submission

Name	View Source	Status
0001628280-20-003395-index-headers.html	Edgar Link	pending
0001628280-20-003395-index.html	Edgar Link	pending
0001628280-20-003395.txt	Edgar Link	pending
0001628280-20-003395-xbrl.zip	Edgar Link	pending
cerc-20191231.xml	Edgar Link	completed
cerc-20191231.xsd	Edgar Link	pending
cerc-20191231_cal.xml	Edgar Link	unprocessable
cerc-20191231_def.xml	Edgar Link	unprocessable
cerc-20191231_lab.xml	Edgar Link	unprocessable
cerc-20191231_pre.xml	Edgar Link	unprocessable
cerc10-k20191231.htm	Edgar Link	pending
cerc800eligibilitya02.jpg	Edgar Link	pending
cercex-2112019.htm	Edgar Link	pending
cercex-2312019.htm	Edgar Link	pending
cercex-3112019.htm	Edgar Link	pending
cercex-3122019.htm	Edgar Link	pending
cercex-3212019.htm	Edgar Link	pending
ex-10152amendmenttoharrell.htm	Edgar Link	pending
ex-1032assignmentoflicense.htm	Edgar Link	pending
ex-410descriptionofregiste.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
rarediseasepipelinefinala01.jpg	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AVTX
Avalo Therapeutics, Inc. Stock $avtx

2020 Q1 Form 10-K Financial Statement

#000162828020003395 Filed on March 11, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVTX Avalo Therapeutics, Inc. Stock $avtx

2020 Q1 Form 10-K Financial Statement

#000162828020003395 Filed on March 11, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVTX
Avalo Therapeutics, Inc. Stock $avtx